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Abstract
Background: One of the causes of Parkinson's disease is mutations in the PARK2 gene. Deletions
and duplications of single exons or exon groups account for a large proportion of the gene
mutations. Direct detection of these mutations can be used for the diagnosis of Parkinson's disease.
Methods: To detect these mutations, we developed an effective technique based on the real-time
TaqMan PCR system, which allows us to evaluate the copynumbers of the PARK2 gene exons by
comparing the intensity of the amplification signals from some exon of this gene with that of the β-
globin gene (the internal control).
Results: We analyzed rearrangements in exons 1–12 of the PARK2 gene in 64 patients from Russia
with early-onset Parkinson's disease. The frequency of these mutations in our patients was 14%.
Conclusion: We have developed a simple, accurate, and reproducible method applicable to the
rapid detection of exon rearrangements in the PARK2 gene. It is suitable for the analysis of large
patient groups, and it may become the basis for a diagnostic test.
Background
Parkinson's disease (PD) is one of the most common neu-
rodegenerative disorders. It has a significant genetic com-
ponent, particularly in individuals with early onset
(younger than 50 years). To date, associations between
three different genes/loci and early-onset Parkinson's dis-
ease (EOPD) have been identified: PARK2, which encodes
parkin [1], PARK6, which encodes PINK1 [2,3], and
PARK7, which encodes DJ-1 [4].
Parkin is expressed primarily in the nervous system and is
one of the family of E3 ubiquitin ligases, which attach
short ubiquitin peptide chains to proteins to tag them for
degradation through the proteasomal pathway [5]. Differ-
ent types of mutations, from point mutations to complex
rearrangements, including deletions and multiplications
of complete exons, have been described in the PARK2
gene [6-10]. Homozygous or compound heterozygous
mutations in PARK2 are considered to cause the disease in
approximately 50% of patients with the rare familial
form, autosomal recessive juvenile PD [5,6,11]. The fre-
quency of PARK2  mutations in patients with sporadic
EOPD may depend on the inclusion criteria and ethnic
background [12,13]. In general, parkin gene mutations
are considered to be autosomal recessive. However, heter-
ozygous mutations have been found to be associated with
subclinical damage to dopamine metabolism in the stria-
tum [14]. It is possible that heterozygous mutations in
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PARK2 can lead in some cases to early-onset or late-onset
sporadic PD or to an increase in the risk of the disease,
given interactions with other factors [15-17]. Therefore, it
is necessary to analyze PARK2 mutations in a large group
of patients with sporadic PD to test this hypothesis. One
distinctive feature of the mutations in this gene is the high
frequency (33%–67%) of exon rearrangements [7-9,18-
20]. This type of mutation is only detectable by gene copy
dosage assays. Here, we describe an effective and quanti-
tative real-time polymerase chain reaction (PCR) method
for the analysis of exon dosage in this gene.
Methods
Patients and samples
We studied two groups of patients: nine with autosomal
recessive juvenile PD and 64 with apparent EOPD, with
an age of onset of ≤ 50 years. All patients were examined
clinically at the Institute of Neurology in the Russian
Academy of Medical Sciences, Moscow. The diagnosis was
confirmed using the UK Parkinson's Disease Brain Bank
Criteria. All patients were assessed using a standard Uni-
fied Parkinson's Disease Rating Scale and Hoehn and Yahr
scores [23]. All participants in this study gave their
informed consent, and the study was approved by the
local ethics committee. Venous whole blood was taken,
and DNA was extracted from peripheral leukocytes by
standard methods [24]. Deletions in PARK2  in the
patients with juvenile PD were detected as described pre-
viously [10,17], and patients' DNA samples were used to
optimize the efficiency of the real-time PCR method
based on TaqMan® technology (Applied Biosystems, Fos-
ter City, CA, USA).
Exon dosage analysis
Primers and probes for exons 1–12 of PARK2  were
designed using Vector NTI Suite 9 software (Invitrogen,
Carlsbad, CA, USA) and the PARK2 sequence (GenBank:
AB009973) (Table 1). The β-globin gene was coamplified
with each individual exon of the PARK2 gene as the inter-
nal standard. Primers and probe sequences for the β-
globin gene were as described previously [25] (Table 1).
PCR was performed in 25 μL reaction volumes containing
10–20 ng of genomic DNA, 1 × PCR buffer (Syntol Corpo-
ration, Moscow, Russia), 2.5 mM MgCl2, 10 pM of the
appropriate primers for the individual exons of PARK2
and the β-globin gene, 200 μM of each dNTP, 1.25 units
of Hot-Rescue Taq DNA polymerase (Syntol Corporation,
Moscow, Russia) and 4 pM of probes for the individual
exons of PARK2 and the β-globin gene, designed using
TaqMan chemistry (Syntol Corporation, Moscow, Rus-
sia). Amplification was performed for 2 min at 50°C, 10
min at 95°C, and 40 cycles of 15 s at 95°C and 50 s at the
appropriate annealing temperature (Tann; see Table 1).
The fluorescence intensity of the PCR products was meas-
ured using an ANA-32 machine (Institute for Analytical
Instrumentation, St. Petersburg, Russia). All samples were
tested in triplicate. We used the value of the cycle thresh-
old (CT) to perform our calculations. The ANA-32
machine software determined the CT for every well by sec-
ond-degree calculation. This method of CT determination
is user independent and is based on a second-derivative
value of the real-time fluorescence intensity curve.
Because three different measurements were obtained per
sample, the average CT (ΔCt) and standard deviation (SD)
were calculated for both PARK2 and the β-globin gene.
The internal control allowed the calculation of the relative
ratio of PARK2 to the β-globin gene concentrations (Rp/b).
This was calculated using ΔCt according to the formula of
Livak et al. [26]:
Rp/b = 2 -(ΔΔCt)
where ΔΔCt = [ΔCt β-globin (control sample) - ΔCt PARK2
(control sample)] - [ΔCt β-globin (patient sample) - ΔCt
PARK2 (patient sample)]. All positive results were con-
firmed at least twice, and the average ratio was calculated.
All samples with homozygous or heterozygous exon rear-
rangements affecting only one exon were confirmed with
an independent set of primers to avoid any false positive
results caused by primer mismatch associated with unde-
tected polymorphisms.
Results
We performed relative quantitative real-time PCR amplifi-
cation based on TaqMan technology to analyze PARK2
exon dosage. With this method, it is possible to analyze
the deletions and duplications of exons 1–12.
Exon dosage analysis was performed for nine genomic
DNA samples from patients with autosomal recessive
juvenile PD. These patients have been described else-
where, and heterozygous PARK2 exon deletions have been
identified in some of them [17].
The relative ratio of PARK2 to the β-globin gene concen-
tration was calculated for all DNA samples (see Table 2).
Based on the observed variability in the values of the
ratios in normal individuals and in positive controls with
heterozygous  PARK2  rearrangements, we considered
ratios between 0.7 and 1.3 as normal. Values lower than
0.6 or higher than 1.4 were interpreted as heterozygous
deletions or duplications of the assessed exon, respec-
tively. In the case of homozygous deletions, the ratio was
0.3 or lower.
We examined 64 Russian patients with EOPD for exon
rearrangements. The majority showed relative PARK2
exon to the β-globin gene ratios of approximately 0.8–1.2
for all exons under study. Alterations in gene dosage were
found in nine patients (14%; Table 3). We detected aBMC Medical Genetics 2007, 8:6 http://www.biomedcentral.com/1471-2350/8/6
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PARK2 exon 5 duplication in two patients (patients 8 and
9). Homozygous deletions were found in two: patients 2
(exon 4) and 5 (exon 3). Heterozygous deletion of a single
exon was found in one patient (exon 3 in patient 6) and
of several exons in four patients (patients 1, 3, 4, and 7;
see Table 3). We could not distinguish heterozygous con-
tiguous multiexonic deletions from compound hetero-
zygous deletions. For precise genotype determination, it
will be necessary to analyze additional intronic DNA
markers or to study the parkin gene deletions in the rela-
tives of patients.
Discussion
Here, we describe a cost-effective technique for the rapid
and accurate detection of exon rearrangements in the
PARK2 gene, using a real-time TaqMan PCR system. Joint
amplification of individual PARK2 exons and the β-globin
gene as the internal control and the use of the least-
squares method to calculate the cycle threshold ensured
the adequacy of the analysis and the repeatability of the
method. For method verification, we examined nine
patients with juvenile autosomal recessive PD whose dele-
tion status determined earlier (three patients without
deletions and six with monoexonic heterozygous dele-
tions). We also studied 64 Russian patients with EOPD
and found exon rearrangements in nine of them using this
method. Our method is suitable for the rapid detection
and screening of exon rearrangements in the parkin gene.
However, for heterozygous contiguous deletions of neigh-
boring exons, it cannot distinguish between a large contig-
uous deletion on a single chromosome and a
combination of two deletions on both chromosomes.
This method is not applicable to the detection of point
mutations or small sequence changes.
To date, several studies have addressed the question of
exon dosage in PARK2 using different approaches [7,8,20-
22]. Lucking et al. [7] performed the first screening to
determine the exon dosage based on semiquantitative
multiplex PCR. However, the amounts of PCR products
were measured in the putative log-linear phase of their
multiplex PCR without consideration of the constant
amplification efficiency of all primer pairs. Other previ-
ously described methods for the detection of the PARK2
gene exon dosage and the method described here are
based on real-time PCR, which provides a precise meas-
urement of the cycle threshold [8,20-22]. One such assay
was based on an intercalating dye (SYBR Green I), which
Table 1: Primers and probe sequences and annealing temperatures used.
Gene/exon Sequences Tann
β-globin Forward primer: 5'-GTGCACCTGACTCCTGAGGAGA-3'
Reverse primer: 5'-CCTTGATACCAACCTGCCCAG-3'
Probe: 5'-FAM-AAGGTGAACGTGGATGAAGTTGGTGG-RTQ1-3'
60°C
PARK2\ex1 Forward primer: 5'-CAGCGGCTCTCCTGGGTTAAA-3'
Reverse primer: 5'-TACGACTCCCAGCAGGCCCT-3'
Probe: 5'-ROX-CCTAGGAATGCGCACGCGCGGAG-RTQ1-3'
60°C
PARK2\ex2 Forward primer: 5'-ATCTCAGGCATGAATGTCAGATT-3'
Reverse primer: 5'-TGACCAGTTGCGTGTGATTT-3'
Probe: 5'-ROX-ATGAGCAATGGAGCTGGCGGCATCC-RTQ1-3'
60°C
PARK2\ex3 Forward primer: 5'-CATTGTGCAGAGACCGTGGAGAA-3'
Reverse primer: 5'-GCTGAGGTCCACCCGAGTCAA-3'
Probe: 5'-ROX-AAATGAATGCAACTGGAGGCGACGACCC-RTQ1-3'
60°C
PARK2\ex4 Forward primer: 5'-TAGCCACTTCTTCTGCTTTT-3'
Reverse primer: 5'-TGCACTGTACCCTGAGTTTT-3'
Probe: 5'-ROX-ATTGCAAAGGCCCCTGTCAAAGAGTGCA-RTQ1-3'
60°C
PARK2\ex5 Forward primer: 5'-TCTTGCTGGGATGATGTTTTAATTCCAAA-3'
Reverse primer: 5'-TTGCAATAAGAGGAATGAAT-3'
Probe: 5'-ROX-AATGCCAATCCCCACACTGCCCTGG-RTQ1-3'
60°C
PARK2\ex6 Forward primer: 5'-CCGTGGAGGGAAGTGACACTAT-3'
Reverse primer: 5'-TGCACCTGATCGCAACAAAT-3'
Probe: 5'-ROX-TGTGCGCGTAATGCAAGTGATGTTCCG-RTQ1-3'
60°C
PARK2\ex7 Forward primer: 5'-GGGTCGTGAACAAACTGCCGATCATT-3'
Reverse primer: 5'-AGGAGCCCCGTCCTGGTTTT-3'
Probe: 5'-ROX-AAGCAAATCACGTGGCGGGAGTTGCAC-RTQ1-3'
60°C
PARK2\ex8 Forward primer: 5'-TCACTCACCTGCTCTTCTCCCAGAAT-3'
Reverse primer: 5'-CAGAGTGAAAGTGACGTTTT-3'
Probe: 5'-ROX-TCAAGGAGTTGGGACAGCCAGCTGTTGG-RTQ1-3'
60°C
PARK2\ex9 Forward primer: 5'-ACCCCACAGCCCAGGCCATT-3'
Reverse primer: 5'-TGCAGATGGGGGGCGTGTTA-3'
Probe: 5'-ROX-TTCGCAGGTGACTTTCCTCTGGTCAGGC-RTQ1-3'
60°C
PARK2\ex10 Forward primer: 5'-GCTTGGAGGAATGAGTAGGGCATT-3'
Reverse primer: 5'-GTTTGCCTTCTGCCGGGAAT-3'
Probe: 5'-ROX-AGGCTTCAAATACGGCACTGCACTCCCC-RTQ1-3'
60°C
PARK2\ex11 Forward primer: 5'-TGGTGGTTTTCTTGATGGTTT-3'
Reverse primer: 5'-AACGCCTTTCCTCTTTGTTT-3'
Probe: 5'-ROX-TCGGCGGCTCTTTCATCGACTCTGTAGG-RTQ1-3'
60°C
PARK2\ex12 Forward primer: 5'-CACGATCTTCCTGAGAAGTCAGACAAT-3'
Reverse primer: 5'-ACAACACTGCATGCGGCAAA-3'
Probe: 5'-ROX-TCTGCGTAGTGTGGGTAAGAGCATGCGG-RTQ1-3'
60°CB
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Table 2: Results of exon dosage analysis for the seventeen previously described PD patients and controls.
Genotype Rp/b (mean ± SD)
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Exon 9 Exon 10 Exon 11 Exon 12
Control 0,95 ± 0,08 0,97 ± 0,06 0,83 ± 0,10 0,99 ± 0,11 1,13 ± 0,05 1,11 ± 0,12 1,03 ± 0,07 0,95 ± 0,08 1,12 ± 0,09 0,98 ± 0,04 1,13 ± 0,05 1,09 ± 0,01
Control 0,88 ± 0,11 1,19 ± 0,10 0,86 ± 0,08 0,88 ± 0,03 0,90 ± 0,16 0,89 ± 0,10 1,00 ± 0,11 0,97 ± 0,04 0,89 ± 0,13 0,96 ± 0,01 0,99 ± 0,07 1,18 ± 0,03
Control 1,02 ± 0,03 1,12 ± 0,11 1,09 ± 0,19 1,03 ± 0,04 0,98 ± 0,06 0,90 ± 0,16 0,96 ± 0,10 1,01 ± 0,11 1,13 ± 0,02 0,98 ± 0,11 1,06 ± 0,07 1,02 ± 0,05
Patient without exon deletion 0,95 ± 0,04 0,83 ± 0,07 0,92 ± 0,10 0,97 ± 0,11 1,03 ± 0,10 1,2 ± 0,14 1,16 ± 0,06 1,07 ± 0,17 0,88 ± 0,12 1,04 ± 0,13 1,03 ± 0,05 1,11 ± 0,12
Patient without exon deletion 1,11 ± 0,02 0,82 ± 0,14 1,15 ± 0,03 1,16 ± 0,08 0,95 ± 0,01 0,96 ± 0,01 0,87 ± 0,05 1,04 ± 0,15 1,18 ± 0,09 0,98 ± 0,10 1,15 ± 0,10 1,03 ± 0,06
Patient without exon deletion 1,01 ± 0,05 0,90 ± 0,11 0,98 ± 0,13 0,89 ± 0,04 0,93 ± 0,06 1,19 ± 0,03 1,14 ± 0,08 1,03 ± 0,12 1,11 ± 0,14 1,10 ± 0,07 0,84 ± 0,11 0,89 ± 0,07
Patient with exon 2 heterozygous deletion 0,91 ± 0,03 0,54 ± 0,05 0,97 ± 0,10 0,92 ± 0,08 0,91 ± 0,06 1,01 ± 0,02 1,13 ± 0,01 1,16 ± 0,05 0,89 ± 0,08 0,82 ± 0,12 0,84 ± 0,13 0,90 ± 0,12
Patient with exon 3 heterozygous deletion 0,98 ± 0,05 1,12 ± 0,09 0,66 ± 0,05 1,13 ± 0,08 0,97 ± 0,07 1,00 ± 0,02 1,01 ± 0,12 0,97 ± 0,04 0,98 ± 0,05 1,12 ± 0,11 0,85 ± 0,13 0,90 ± 0,07
Patient with exon 4 heterozygous deletion 0,97 ± 0,02 0,95 ± 0,06 1,13 ± 0,08 0,60 ± 0,08 1,11 ± 0,15 0,86 ± 0,03 0,98 ± 0,09 0,91 ± 0,07 0,96 ± 0,05 1,08 ± 0,02 1,07 ± 0,03 1,08 ± 0,02
Patient with exon 5 heterozygous deletion 1,05 ± 0,02 0,95 ± 0,05 0,99 ± 0,15 1,19 ± 0,07 0,60 ± 0,15 1,02 ± 0,11 1,03 ± 0,09 0,85 ± 0,04 0,84 ± 0,08 0,98 ± 0,09 0,93 ± 0,03 1,03 ± 0,15
Patient with exon 6 heterozygous deletion 1,08 ± 0,01 1,04 ± 0,01 1,14 ± 0,07 0,97 ± 0,03 0,89 ± 0,09 0,59 ± 0,04 0,99 ± 0,03 1,01 ± 0,02 1,11 ± 0,01 1,00 ± 0,04 1,13 ± 0,02 0,96 ± 0,06
Patient with exon 7 heterozygous deletion 0,99 ± 0,09 0,97 ± 0,03 0,85 ± 0,02 0,88 ± 0,01 1,04 ± 0,08 1,2 ± 0,06 0,58 ± 0,09 1,09 ± 0,11 1,02 ± 0,02 1,05 ± 0,07 0,96 ± 0,03 0,93 ± 0,04B
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Table 3: Results of exon dosage analysis for the nine PD patients with exon deletions and duplications.
Genotype Rp/b (mean ± SD)
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Exon 9 Exon 10 Exon 11 Exon 12
Patient 1 0,98 ± 0,01 1,01 ± 0,17 0,57 ± 0,02 0,55 ± 0,05 0,60 ± 0,15 0,59 ± 0,04 0,58 ± 0,09 1,03 ± 0,07 0,98 ± 0,12 1,04 ± 0,02 1,06 ± 0,02 1,12 ± 0,10
Patient 2 1,03 ± 0,04 0,93 ± 0,14 1,05 ± 0,03 0,01 ± 0,01 0,95 ± 0,01 0,96 ± 0,02 0,88 ± 0,06 1,07 ± 0,02 0,89 ± 0,04 0,98 ± 0,03 1,06 ± 0,01 1,04 ± 0,02
Patient 3 1,08 ± 0,03 0,90 ± 0,04 0,47 ± 0,03 0,61 ± 0,10 0,93 ± 0,06 1,09 ± 0,03 1,11 ± 0,02 1,05 ± 0,04 1,11 ± 0,03 1,02 ± 0,06 0,94 ± 0,03 0,98 ± 0,03
Patient 4 1,00 ± 0,02 0,54 ± 0,05 0,63 ± 0,02 0,60 ± 0,08 0,91 ± 0,06 1,05 ± 0,11 1,03 ± 0,02 1,21 ± 0,05 0,94 ± 0,03 0,82 ± 0,14 0,88 ± 0,02 0,91 ± 0,12
Patient 5 0,99 ± 0,06 1,01 ± 0,08 0,01 ± 0,02 1,13 ± 0,08 0,97 ± 0,07 1,00 ± 0,02 1,06 ± 0,12 0,97 ± 0,04 1,02 ± 0,05 1,15 ± 0,04 0,87 ± 0,04 0,94 ± 0,03
Patient 6 0,89 ± 0,07 0,93 ± 0,02 0,66 ± 0,04 0,92 ± 0,03 1,11 ± 0,15 0,89 ± 0,04 0,93 ± 0,10 0,91 ± 0,08 1,13 ± 0,02 1,08 ± 0,01 1,07 ± 0,06 1,08 ± 0,01
Patient 7 0,86 ± 0,04 0,95 ± 0,12 0,61 ± 0,09 0,63 ± 0,08 0,57 ± 0,12 1,03 ± 0,10 1,06 ± 0,08 0,83 ± 0,05 0,94 ± 0,07 0,97 ± 0,02 0,98 ± 0,07 1,01 ± 0,11
Patient 8 1,02 ± 0,04 1,14 ± 0,01 1,01 ± 0,07 0,97 ± 0,03 1,41 ± 0,16 0,99 ± 0,04 0,99 ± 0,03 1,01 ± 0,06 1,01 ± 0,07 1,03 ± 0,08 1,02 ± 0,03 0,99 ± 0,02
Patient 9 1,21 ± 0,03 0,97 ± 0,10 0,93 ± 0,02 1,02 ± 0,06 1,43 ± 0,17 1,02 ± 0,06 1,13 ± 0,01 1,01 ± 0,12 1,11 ± 0,03 1,03 ± 0,08 0,98 ± 0,04 0,96 ± 0,05BMC Medical Genetics 2007, 8:6 http://www.biomedcentral.com/1471-2350/8/6
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functions as a fluorescent reporter, and used unlabeled
primers [20]. Because that method uses only a single flu-
orescent reporter, two independent amplifications (of
PARK2 and the β-globin gene) are necessary for each DNA
sample. However, application of the LightCycler (Roche
Applied Science, Indianapolis, IN, USA) or TaqMan sys-
tem allows us to carry out only one multiplex amplifica-
tion reaction for each DNA sample [8,21,22]. This
improves sensitivity and repeatability and reduces the
time taken. Here, we used a combination of ROX-labeled
parkin gene and FAM-labeled β-globin gene probes in a
single-tube multiplex PCR amplification. To avoid prob-
lems of the possible loss of signal when there are varia-
tions within the binding sites, we selected probes with low
melting temperatures. The annealing temperature we used
was 60°C. In the case of a mismatch, such probes will still
generate a signal.
Both the TaqMan and the LightCycler systems allow the
application of quantitative real-time PCR assays by using
labeled oligonucleotide probes, which generate sequence-
specific signals. In the TaqMan system, only one probe is
used for each locus, whereas in the LightCycler system,
two hybridization probes are necessary, so it is more com-
plicated.
Two other groups have measured exon dosage based on
TaqMan technology [21,22]. Maruyama et al. [21] per-
formed a PCR assay with TaqMan probes but only for
exons 1–5. However, rearrangements in other exons (7–
12) have been described in some populations of patients
with PD [10,13,15,17]. Thus, the determination of those
deletions and duplications is very important for diagnos-
tic purposes. Sinha et al. [22] used an 84-bp fragment of a
single-copy human β-actin gene as the internal control.
However, in that technique variant, a standard curve of
human genomic DNA concentrations must be generated
for every PCR run [22], so it is more complicated and less
repeatable than our method.
All these methods are based on different types of real-time
PCR. Recently, a new approach has been described, called
multiplex ligation-dependent probe amplification
(MLPA). MLPA is based on the combination of a ligation
reaction and standard PCR followed by electrophoresis. It
has been shown that this method is also applicable to
exon dosage analysis [27]. However, a direct relationship
between exon dosage and the amount of the ligation reac-
tion product has not yet been proved. Thus, MLPA can be
considered only as a semiquantitative method and not as
an alternative to real-time-PCR-based methods. In our
opinion, it would be ideal to combine real-time TaqMan
PCR and MLPA to confirm the results further.
Conclusion
This TaqMan real-time PCR methodology can be applied
to the rapid and precise screening of exon rearrangements
in the PARK2 gene in patients with PD. It analyzes all rel-
evant deletions and duplications of exons 1–12. The
determination of the TaqMan-based cycle threshold is
more precise than earlier methods based on SYBR Green I
labeling. A very precise measurement of exon dosage is
possible using a second-derivative value of the real-time
fluorescence intensity curve. This method is applicable to
the analysis of large patient groups and may become the
basis for a diagnostic test.
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